Browse By Cell Line Result Page of OvirusTdb
The total number of records retrieved from this search are 28. Click on ID to see further detail.
IDOV_943 | Virus nameAdenovirus | Virus strainwild type | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineAlabama-Birmingham | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10 virus particle/cell | In-vitro result80% cancer cell survival after 2 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_944 | Virus nameAdenovirus | Virus strainwild type | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineAlabama-Birmingham | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration100 virus particle/ cell | In-vitro result70% cancer cell survival after 2 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_945 | Virus nameAdenovirus | Virus strainwild type | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineAlabama-Birmingham | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration1000 virus particle/ cell | In-vitro result70% cancer cell survival after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_946 | Virus nameAdenovirus | Virus strainwild type | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineAlabama-Birmingham | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10000 virus particle/ cell | In-vitro result80% cancer cell survival after 2 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_975 | Virus nameAdenovirus | Virus strainwild type | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineAlabama-Birmingham | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10 virus particle/cell | In-vitro result80% cancer cell survival after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_976 | Virus nameAdenovirus | Virus strainwild type | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineAlabama-Birmingham | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration100 virus particle/ cell | In-vitro result80% cancer cell survival after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_977 | Virus nameAdenovirus | Virus strainwild type | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineAlabama-Birmingham | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration1000 virus particle/ cell | In-vitro result50% cancer cell survival after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_978 | Virus nameAdenovirus | Virus strainwild type | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineAlabama-Birmingham | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10000 virus particle/ cell | In-vitro result20% cancer cell survival after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1055 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10 pfu/cell | In-vitro result100% cell survival after 2 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1056 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration100 pfu/cell | In-vitro result80% cell survival after 2 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1057 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration1000 pfu/cell | In-vitro result75% cell survival after 2 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1058 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10000 pfu/cell | In-vitro result30% cell survival after 2 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1059 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10 pfu/cell | In-vitro result100% cell survival after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1060 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration100 pfu/cell | In-vitro result20% cell survival after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1061 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration1000 pfu/cell | In-vitro result20% cell survival after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1062 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10000 pfu/cell | In-vitro result100% cell killing after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1063 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10 pfu/cell | In-vitro result100% cell survival after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1064 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration100 pfu/cell | In-vitro result100% cell killing after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1065 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration1000 pfu/cell | In-vitro result100% cell killing after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1066 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10000 pfu/cell | In-vitro result100% cell killing after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1067 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10 pfu/cell | In-vitro result100% cell survival after 8 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1068 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration100 pfu/cell | In-vitro result100% cell killing after 8 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1069 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration1000 pfu/cell | In-vitro result100% cell killing after 8 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_1070 | Virus nameHerpes simplex virus | Virus strainHSV-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant NV1066 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineMediGene Inc. San Diego, CA | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE | Concentration of cell line4.0E+3 cells per well | In-vitro toxicityNA | AssayNA | In-vitro virus concentration10000 pfu/cell | In-vitro result100% cell killing after 8 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedApoptosis induction and cspase 3 activation | Immunogenic effectNA | Clinical trialNA | PMID15570577 |
IDOV_2891 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineLaboratory grown own culture | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE2 | Concentration of cell line5.0E+3 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.01 MOI | In-vitro result50% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID23816608 |
IDOV_2892 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineLaboratory grown own culture | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE2 | Concentration of cell line5.0E+3 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result40% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID23816608 |
IDOV_2893 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineLaboratory grown own culture | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE2 | Concentration of cell line5.0E+3 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result38% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID23816608 |
IDOV_2894 | Virus nameVaccinia virus | Virus strainvvDD | Virus genome typeDNA | Virus familyPoxviridae | Virus genome modificationDeletion of TK gene and vaccinia growth factor | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineLaboratory grown own culture | Origin of cell lineNeuroblastoma cell line | Cell lineSKNBE2 | Concentration of cell line5.0E+3 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration10 MOI | In-vitro result20% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID23816608 |